From 13-17 July, we’ll be in Kigali, Rwanda to attend the International AIDS Conference (IAS 2025). As the premier global scientific conference dedicated to advancing HIV science and advocacy, IAS will bring together thousands of scientists, healthcare professionals and advocates from all around the world all united under one goal – to make HIV history.
SHOWCASING OUR INNOVATIVE PORTFOLIO AT IAS 2025
At ViiV Healthcare, we have a big ambition - to end the HIV epidemic for everyone. Until then, we won’t stop pushing the boundaries of HIV science and exploring new ways of treating and preventing HIV in order to achieve our mission of leaving no person living with, or impacted by, HIV behind.
At IAS 2025 we’ll:
- Share data from 18 abstracts and 24 ViiV-supported and collaborative studies from our INSTI-led treatment and prevention portfolio.
- Present interim data from our Positive Perspectives 3 (PP3) study, which, once complete, will be one of the largest surveys of people living with HIV, including more than 3000 participants across 29 countries.
You can find out more about the conference programme here and don’t forget to come say hi at our booth!
100% DEDICATED
Our commitment to support people impacted by HIV, no matter who they are or where they live is unwavering and at IAS 2025, we'll be using our platform to amplify the voices of the HIV community.
NOT ATTENDING IAS?
Follow along on our socials for daily updates from our leaders and community partners. We'll be discussing topics such as the role of Real-World Evidence, the role of Undetectable = Untransmittable (U=U) in combatting HIV stigma, and the importance of shared decision making between people living with HIV and their healthcare providers.
YOU MAY ALSO BE INTERESTED IN
The process of identifying, creating and developing generally well-tolerated and effective innovative HIV therapies is complex and requires ongoing collaboration between research teams that work in many different areas of medicines development.
Discover the importance of representative research for HIV treatment for people living with HIV.
Understanding the global barriers to treatment, use, and adherence is crucial to making U=U a reality for all people living with HIV.
RELATED PAGES:
Get access to the latest press releases, company statements, and the main conferences and events about HIV and AIDS.
ViiV Exchange is our online portal for Healthcare Professionals; allowing access to latest data and information in relation to our HIV medicines.
Learning to navigate life with HIV can take time but it should not stop you from living the life you want. Read more about how to live well with HIV.
NP-GBL-HVX-COCO-230008 June 2025
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
